Disease Overview：Premature Ovarian Insufficiency（POI）
Premature Ovarian Insufficiency (POI), formerly known as premature ovarian failure, is a clinical syndrome characterized by loss of ovarian function before age 40, marked by amenorrhea, elevated follicle-stimulating hormone (FSH > 25 IU/L on two occasions >4 weeks apart), and estrogen deficiency. It affects approximately 1% of women under 40 and may result from genetic factors (e.g., FMR1 premutation, Turner mosaicism), autoimmune disorders, iatrogenic causes (chemotherapy/radiation), or idiopathic mechanisms. Symptoms include infertility, vasomotor instability, vaginal atrophy, and increased long-term risks of osteoporosis and cardiovascular disease. Diagnosis requires comprehensive evaluation—hormonal profiling, anti-Müllerian hormone (AMH) assessment, pelvic ultrasound, and karyotyping—to differentiate POI from transient ovarian suppression or other endocrinopathies. While spontaneous pregnancy occurs in 5–10% of cases, most patients require individualized fertility preservation strategies, hormone replacement therapy (HRT), or donor-egg IVF to achieve parenthood.
China offers distinct advantages for international patients seeking POI management. Leading reproductive medicine centers—such as those affiliated with Peking University Third Hospital and Shanghai Jiao Tong University School of Medicine—combine deep expertise in ovarian reserve assessment, precision HRT protocols, and advanced assisted reproductive technologies (ART), including time-lapse embryo monitoring and preimplantation genetic testing. Clinical outcomes align with global benchmarks: cumulative live birth rates per donor-egg IVF cycle exceed 60% in top-tier programs. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising regulatory standards—Chinese ART clinics operate under strict National Health Commission oversight and ISO-certified quality systems. As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with certified reproductive endocrinologists, verifying hospital credentials, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and multilingual clinical liaison services—all tailored to address concerns about efficacy, safety, and financial predictability.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Premature Ovarian Insufficiency (POI)
Non-Surgical / Conservative / Medication Options
*Target Criteria:* Confirmed POI (FSH >25 IU/L on two occasions >4 weeks apart, amenorrhea <40 years), no contraindications to hormone therapy (e.g., active thrombosis, ER+ breast cancer).
- •Standard Hormone Replacement Therapy (HRT)
- Initial workup: Pelvic ultrasound ($45), AMH ($65), FSH/LH/E2 ($38), thyroid panel ($22), liver/kidney function ($18) → $188 total - Monthly medication cost: $22–$38 (generic vs. branded estradiol/dydrogesterone) - Annual follow-up: Repeat FSH/E2 + bone density scan (DXA, $75) → $113/year
- •Transdermal HRT (for thrombosis risk or GI intolerance)
- Patch + progesterone monthly supply: $58–$92 - Annual DXA + lipid panel ($28): $120/year
- •Adjunctive Therapies
- Low-dose testosterone (off-label, monitored): $48/month (testosterone gel + quarterly DHEA/total T labs: $42)
Surgical / Procedural / Interventional Options
*Eligibility:* Confirmed POI with desire for fertility; exclusion of genetic causes (e.g., Turner mosaicism), normal karyotype, and intact ovarian tissue on ultrasound/MRI.
- •Ovarian Rejuvenation (PRP Intraovarian Injection)
- Procedure (ultrasound-guided bilateral intraovarian PRP injection): $1,280–$1,850 - Post-procedure monitoring (3 cycles of E2/FSH tracking): $92
- •Donor Egg IVF (Standard Pathway)
- Recipient prep (endometrial receptivity analysis + hysteroscopy): $890 - Cycle (stimulation, retrieval, ICSI, blastocyst culture, frozen embryo transfer): $4,200–$5,600 - Embryo freezing/storage (1st year): $320
Special/Complex Condition Management
- •POI with Autoimmune Polyglandular Syndrome: Add adrenal autoantibodies ($36), cortisol stimulation test ($85); annual endocrinology consult: $110
- •POI + Primary Ovarian Lymphoma (rare): Oncology referral; PET-CT ($1,020), biopsy ($380), chemotherapy (R-CHOP cycle): $2,800–$3,500/cycle
Quick Selection Guide
- •<35 years, fertility desire, AMH >0.5 ng/mL: Start PRP ($1,280–$1,850) + HRT; budget $2,000–$3,000 initial
- •35–39 years, no fertility goal, comorbid osteoporosis: Transdermal HRT + annual DXA ($120/year); total Year 1: $720
- •Any age, severe vasomotor symptoms + cardiovascular risk: Transdermal HRT + lipid panel monitoring ($120/year); avoid oral estrogen
- •Budget-constrained (<$500/year): Generic oral HRT + vitamin D/calcium ($280/year); skip DXA until age 45 or fracture risk assessment
- •POI + confirmed autoimmune adrenal insufficiency: Immediate glucocorticoid replacement + specialist endocrine care ($1,200/year)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Premature Ovarian Insufficiency Medical Vacation Packages
Curated transparent all-inclusive packages combining Premature Ovarian Insufficiency treatment with China top medical destinations:
